Literature DB >> 1525003

Yersinia infections in patients with homozygous beta-thalassemia associated with iron overload and its treatment.

N S Green1.   

Abstract

Patients with homozygous beta-thalassemia are at increased risk of serious infections. Yersinia enterocolitica is an organism with a predilection for these and other iron-overloaded patients. Three young adult patients with beta-thalassemia who were chronically transfused and developed yersiniosis are reported. Iron overload and desferrioxamine use are predisposing factors, as supported by clinical, animal, and in vitro data. Iron excess both immunologically compromises the host and greatly enhances yersinial growth. Desferrioxamine may make host iron even more bioavailable to Yersinia. Recognition of this association and unusual manifestations in these patients such as an appendicitis-like syndrome may direct clinicians to earlier antiyersinial therapy and temporary cessation of chelation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1525003     DOI: 10.3109/08880019209016592

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  3 in total

1.  Iron sucrose impairs phagocytic function and promotes apoptosis in polymorphonuclear leukocytes.

Authors:  Hirohito Ichii; Yuichi Masuda; Tania Hassanzadeh; Mateen Saffarian; Sastry Gollapudi; Nosratola D Vaziri
Journal:  Am J Nephrol       Date:  2012-06-19       Impact factor: 3.754

2.  Hand-assisted laparoscopic surgery with a Pfannenstiel incision in beta-thalassemia patients: initial experience.

Authors:  Emmanuel Leandros; Nicholas Alexakis; Konstadinos Albanopoulos; Dimitris Dardamanis; Markisia Karagiorga; Ilias Gomatos; Stefanos Papadopoulos; Christos Bacoyiannis; John Bramis
Journal:  World J Surg       Date:  2006-07       Impact factor: 3.352

3.  Treating thalassemia major-related iron overload: the role of deferiprone.

Authors:  Vasilios Berdoukas; Kallistheni Farmaki; Susan Carson; John Wood; Thomas Coates
Journal:  J Blood Med       Date:  2012-10-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.